Neogen Corporation (NEOG) Cash Flow Statement

The OCF/NI ratio across the trailing quarters is extraordinarily volatile, ranging from -4.94 to +1.42, confirming that GAAP net income has been rendered analytically unreliable by non-cash merger accounting charges. The structural issue is that Neogen's operating cash generation of roughly $16–40 million per quarter (excluding 2025Q1) appears consistent with underlying cash operations, yet the enormous D&A load from acquired intangible amortization means the company's reported losses materially overstate the cash burn. However, investors should note that even the $161 million in cumulative OCF over ten quarters is modest relative to the company's $188 million cumulative capital expenditure, suggesting that the business as currently configured is not generating meaningful free cash to service the debt likely incurred in the 3M transaction.

The FCF margin swing from -26.0% in 2025Q1 to 19.3% in 2026Q2 reflects both lumpy working capital movements and volatile capital expenditure rather than any structural improvement in cash generation. The most recent quarter (2027Q1) posted $4.7 million in FCF on a 2.1% margin, which while positive, does not represent a meaningful acceleration from the $2.4 million in FCF generated two years prior. Given the company's stated gross margin recovery and the stabilization of operating cash flow around $20–30 million per quarter in recent periods, there appears to be a path to more consistent FCF, but investors should monitor whether capex normalizes or remains elevated to judge whether that path materializes.

The extreme capex volatility—ranging from $38.4 million in 2025Q1 to just $4.0 million in 2026Q4—suggests lumpy facility consolidation or integration-driven capital programs rather than a steady maintenance cycle. The sharp reduction in capex to 1.8% of revenue in 2026Q4 and 3.7% in 2027Q1 could indicate that the bulk of merger-related capital deployment is complete, though it is also possible that necessary maintenance capex is being deferred. With D&A running at roughly $29–36 million per quarter against capex of only $4–8 million in the most recent two quarters, Neogen is now significantly under-investing relative to its depreciation run rate, which may create a future capital catch-up requirement for aging diagnostic manufacturing infrastructure.

The complete absence of shareholder returns across two and a half years—combined with the fact that cumulative FCF is essentially zero—suggests that management is prioritizing balance sheet repair and integration over capital return. The symmetrical $121.7 million acquisition outflow in Q3 2026 and inflow in Q1 2026 may represent a structural adjustment or partial divestiture related to the 3M transaction, though the precise nature warrants closer examination of the filings. With operating margins still negative and the company generating modest positive FCF only recently, the decision to retain all cash appears prudent given the integration risk, but it also means that equity investors have no cash yield to offset the ongoing reported losses.